Toxicity Profile With a Large Prostate Volume After External Beam Radiotherapy for Localized Prostate Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 70, Issue 1, 2008, Pages 83-89

  Pinkawa, Michael ^a   Fischedick, Karin ^a   Asadpour, Branka ^a   Gagel, Bernd ^a   Piroth, Marc D ^a   Nussen, Sandra ^a   Eble, Michael J ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Prostate neoplasm; Prostate volume; Quality of life; Radiotherapy; Toxicity

Indexed keywords

BIOLOGICAL ORGANS; HORMONES; ONCOLOGY; RADIOTHERAPY; TOXICITY;

HORMONAL THERAPY; PROSTATE NEOPLASM; PROSTATE VOLUME; QUALITY OF LIFE;

TUMORS;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; DYSURIA; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; POLLAKISURIA; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; QUESTIONNAIRE; SYMPTOM; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; AREA UNDER CURVE; HEALTH CARE SURVEYS; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROSPECTIVE STUDIES; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RECTUM; URINARY BLADDER; URINATION DISORDERS;

EID: 37048999749     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.05.051     Document Type: Article

References (38)

1. Speight J.L., and Roach M. Radiotherapy in the management of clinically localized prostate cancer: Evolving standards, consensus, controversies and new directions. J Clin Oncol 23 (2005) 8176-8185
2. Michalski J.M., Winter K., Purdy J.A., et al. Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II. Int J Radiat Oncol Biol Phys 56 (2003) 192-198
3. Goldner G., Wachter-Gerstner N., Wachter S., et al. Acute side effects during 3-D-planned conformal radiotherapy of prostate cancer. Differences between patient's self-reported questionnaire and the corresponding doctor's report. Strahlenther Onkol 179 (2003) 320-327
4. Akimoto T., Muramatsu H., Takahashi M., et al. Rectal bleeding after hypofractionated radiotherapy for prostate cancer: Correlation between clinical and dosimetric parameters and the incidence of grade 2 or worse rectal bleeding. Int J Radiat Oncol Biol Phys 60 (2004) 1033-1039
5. Cheung R., Tucker S.L., Ye J.S., et al. Characterization of rectal normal tissue complication probability after high-dose external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 58 (2004) 1513-1519
6. Jackson A., Skwarchuk M.W., Zelefsky M.J., et al. Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose-volume histograms. Int J Radiat Oncol Biol Phys 49 (2001) 685-698
7. Skwarchuk M.W., Jackson A., Zelefsky M.J., et al. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): Multivariate analysis and dose-response. Int J Radiat Oncol Biol Phys 47 (2000) 103-113
8. Zapatero A., Garcia-Vicente F., Modolell I., et al. Impact of mean rectal dose on late rectal bleeding after conformal radiotherapy for prostate cancer: Dose-volume effect. Int J Radiat Oncol Biol Phys 59 (2004) 1343-1351
9. Karlsdottir A., Johannessen D.C., Muren L.P., et al. Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer. Radiother Oncol 71 (2004) 43-53
10. Michalski J.M., Purdy J.A., Winter K., et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys 46 (2000) 391-402
11. Selek U., Cheung R., Lii M., et al. Erectile dysfunction and radiation dose to penile base structures: A lack of correlation. Int J Radiat Oncol Biol Phys 59 (2004) 1039-1046
12. Pinkawa M., Fischedick K., Asadpour B., et al. Low-grade toxicity after conformal radiation therapy for prostate cancer-impact of bladder volume. Int J Radiat Oncol Biol Phys 64 (2006) 835-841
13. Dearnaley D.P., Khoo V.S., and Norman A.R. Comparison of radiation side effects of conformal and conventional radiotherapy in prostate cancer: A randomized trial. Lancet 353 (1999) 267-272
14. Koper P.C., Stroom J.C., van Putten W.L., et al. Acute morbidity reduction using 3DCRT for prostate carcinoma: A randomized study. Int J Radiat Oncol Biol Phys 43 (1999) 727-734
15. Koper P.C., Jansen P., van Putten W., et al. Gastro-intestinal and genito-urinary morbidity after 3D conformal radiotherapy of prostate cancer: Observations of a randomized trial. Radiother Oncol 73 (2004) 1-9
16. Zelefsky M.J., and Harrison A. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: Reducing the potential morbidity of therapy. Urology 49 (1997) 38-45
17. Lilleby W., Dale E., Olsen D.R., et al. Changes in treatment volume of hormonally treated and untreated cancerous prostate and its impact on rectal dose. Acta Oncol 42 (2003) 10-14
18. Krupski T., Bissonette E.A., Petroni G.R., et al. The impact of prostate volume following neoadjuvant androgen deprivation on quality of life and voiding symptoms in patients undergoing permanent prostate brachytherapy. Eur Urol 43 (2003) 467-472
19. Locke J., Ellis W., Wallner K., et al. Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: A prospective study. Int J Radiat Oncol Biol Phys 52 (2002) 712-719
20. Sherertz T., Wallner K., Wang H., et al. Long-term urinary function after transperineal brachytherapy for patients with large prostate glands. Int J Radiat Oncol Biol Phys 51 (2001) 1241-1245
21. Pinkawa M., Gagel B., Piroth M.D., et al. Changes of dose delivery distribution within the first month after permanent interstitial brachytherapy for prostate cancer. Strahlenther Onkol 182 (2006) 525-530
22. International Commission on Radiation Units and Measurements. ICRU report 50: Prescribing, recording and reporting photon beam therapy (1993), ICRU, Bethesda, MD
23. Wei J.T., Dunn R.L., Litwin M.S., et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 56 (2000) 899-905
24. Merrick G.S., Butler W.M., Wallner K.E., et al. Long-term urinary quality of life after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 56 (2003) 454-461
25. Ososba D., Rodrigues G., Myles J., et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16 (1998) 139-144
26. Brenner D.J. Fractionation and late rectal toxicity. Int J Radiat Oncol Biol Phys 60 (2004) 1013-1015
27. Goldner G., Tomicek B., Becker G., et al. Proctitis after external-beam radiotherapy for prostate cancer classified by Vienna Rectoscopy Score and correlated with EORTC/RTOG score for late rectal toxicity: Results of a prospective multicenter study of 166 patients. Int J Radiat Oncol Biol Phys 67 (2007) 78-83
28. van der Kogel A.J. Radiation response and tolerance of normal tissues. In: Steel G.G. (Ed). Basic clinical radiobiology (2002), Arnold, London 30-41
29. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 360 (2002) 103-108
30. D'Amico A.V., Manola J., Loffredo M., et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 292 (2004) 821-827
31. Hanks G.E., Pajak T.F., Porter A., et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21 (2003) 3972-3978
32. Lawton C.A., Winter K., Murray K., et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49 (2001) 937-946
33. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 (2005) 1285-1290
34. Roach III M., DeSilvio M., Lawton C., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21 (2003) 1904-1911
35. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337 (1997) 295-300
36. Feigenberg S.J., Hanlon A.L., Horwitz E.M., et al. Long-term androgen deprivation increases grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 62 (2005) 397-405
37. Schultheiss T.E., Lee W.R., Hunt M.A., et al. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 37 (1997) 3-11
38. Davis J.W., Kuban D.A., Lynch D.F., et al. Quality of life after treatment for localized prostate cancer: Differences based on treatment modality. J Urol 166 (2001) 947-952